Cyto 014
Alternative Names: Biobetter BoNT - CytoDel; Botulinum neurotoxin - CytoDel; Cyto-014Latest Information Update: 15 Dec 2021
At a glance
- Originator CytoDel; NYU Grossman School of Medicine
- Developer CytoDel
- Class Antispasmodics; Bacterial proteins; Bacterial toxins; Muscle relaxants; Recombinant proteins; Urologics
- Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Neuromuscular blocking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Dystonia
Most Recent Events
- 07 Jan 2021 CytoDel has patent protection for molecular design of botulinum neurotoxin in the US (CytoDel website, January 2021)
- 07 Jan 2021 Preclinical trials in Dystonia in USA (Parenteral) (CytoDel website, January 2021)